Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A post-hoc pooled analysis to evaluate efficacy and safety of insulin glargine 300 U/mL in insulin-naïve people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy.
Cheng AYY, Mauricio D, Ritzel R, Al-Sofiani ME, Bailey T, Aileen Mabunay M, Bonnemaire M, Melas-Melt L, Mimouni S, Davies M. Cheng AYY, et al. Among authors: bonnemaire m. Diabetes Res Clin Pract. 2024 Sep 27;217:111871. doi: 10.1016/j.diabres.2024.111871. Online ahead of print. Diabetes Res Clin Pract. 2024. PMID: 39343145 Free article.
iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
Guja C, Kis JT, Haluzík M, Bonnemaire M, Bigot G, Tournay M, Freemantle N, Seufert J. Guja C, et al. Among authors: bonnemaire m. Diabetes Obes Metab. 2023 Jun;25(6):1723-1730. doi: 10.1111/dom.15027. Epub 2023 Mar 21. Diabetes Obes Metab. 2023. PMID: 36810874
Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.
Haluzík M, Seufert J, Guja C, Bonnemaire M, Bigot G, Tournay M, Kis JT, Freemantle N. Haluzík M, et al. Among authors: bonnemaire m. Diabetes Ther. 2023 Apr;14(4):639-652. doi: 10.1007/s13300-023-01375-8. Epub 2023 Feb 14. Diabetes Ther. 2023. PMID: 36787044 Free PMC article.
Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database.
Müller-Wieland D, Freemantle N, Bonadonna RC, Mauquoi C, Bigot G, Bonnemaire M, Gourdy P, Mauricio D. Müller-Wieland D, et al. Among authors: bonnemaire m. Diabetes Ther. 2023 Feb;14(2):401-413. doi: 10.1007/s13300-022-01356-3. Epub 2023 Jan 4. Diabetes Ther. 2023. PMID: 36596946 Free PMC article.
Does Gender Influence the Effectiveness and Safety of Insulin Glargine 300 U/ml in Patients with Uncontrolled Type 2 Diabetes? Results from the REALI European Pooled Analysis.
Gourdy P, Bonadonna RC, Freemantle N, Mauricio D, Müller-Wieland D, Bigot G, Mauquoi C, Ciocca A, Bonnemaire M. Gourdy P, et al. Among authors: bonnemaire m. Diabetes Ther. 2022 Jan;13(1):57-73. doi: 10.1007/s13300-021-01179-8. Epub 2021 Nov 16. Diabetes Ther. 2022. PMID: 34784005 Free PMC article.
Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
Rosenstock J, Emral R, Sauque-Reyna L, Mohan V, Trescolí C, Al Sifri S, Lalic N, Alvarez A, Picard P, Bonnemaire M, Demil N, McCrimmon RJ; SoliMix Trial Investigators. Rosenstock J, et al. Among authors: bonnemaire m. Diabetes Care. 2021 Jun 28;44(10):2361-70. doi: 10.2337/dc21-0393. Online ahead of print. Diabetes Care. 2021. PMID: 34183429 Free PMC article.
26 results